Effect of growth hormone replacement therapy on pituitary hormone secretion and hormone replacement therapies in GHD adults

Erika Hubina, Henriette Mersebach, Åse Krogh Rasmussen, Anders Juul, Simone Bjerregaard Sneppen, M. Góth, Ulla Feldt-Rasmussen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: We tested the impact of commencement of GH replacement therapy in GH-deficient (GHD) adults on the circulating levels of other anterior pituitary and peripheral hormones and the need for re-evaluation of other hormone replacement therapies, especially the need for dose changes. Methods: 22 GHD patients were investigated in a double-blind randomized study and 90 GHD patients in an open study at baseline and after 6 and 12 months of GH replacement therapy. Results: In the placebo-controlled trial, the FT 3 levels increased after 6 months in the GH-treated group, and in the open study the FT3 levels tended to increase. Other hormone concentrations did not change in either part of the study. Four patients required an increase in thyroxine dose, while 2 patients needed dose reduction. One originally euthyroid patient required thyroxine replacement. Two patients with originally conserved pituitary-adrenal function developed ACTH insufficiency. The hydrocortisone dose was increased in 1 and decreased in 1 of the 66 patients with secondary hypocortisolism. None of the females required any adjustment of sex hormone replacement therapy. Two of 37 males needed dose increase of testosterone, while 1 needed dose reduction. Conclusion: GH replacement therapy required dose adjustments regarding other hormone replacement therapies in 12.2% (n = 11), while initiation of new hormone replacement was performed in 3.3% (n = 3) of the 90 patients during the 1-year follow-up. Monitoring of pituitary hormone axes is advisable after commencement of GH replacement therapy, since changes of hormone replacement therapy was observed in a small but clinically significant number of patients.

Original languageEnglish
Pages (from-to)211-217
Number of pages7
JournalHormone Research
Volume61
Issue number5
DOIs
Publication statusPublished - 2004

Fingerprint

Pituitary Hormones
Hormone Replacement Therapy
Growth Hormone
Thyroxine
Hormones
Anterior Pituitary Hormones
Gonadal Steroid Hormones
Therapeutics
Double-Blind Method
Adrenocorticotropic Hormone
Hydrocortisone
Placebos

Keywords

  • Growth hormone replacement
  • Pituitary function
  • Pituitary substitution therapy

ASJC Scopus subject areas

  • Endocrinology

Cite this

Hubina, E., Mersebach, H., Rasmussen, Å. K., Juul, A., Sneppen, S. B., Góth, M., & Feldt-Rasmussen, U. (2004). Effect of growth hormone replacement therapy on pituitary hormone secretion and hormone replacement therapies in GHD adults. Hormone Research, 61(5), 211-217. https://doi.org/10.1159/000076538

Effect of growth hormone replacement therapy on pituitary hormone secretion and hormone replacement therapies in GHD adults. / Hubina, Erika; Mersebach, Henriette; Rasmussen, Åse Krogh; Juul, Anders; Sneppen, Simone Bjerregaard; Góth, M.; Feldt-Rasmussen, Ulla.

In: Hormone Research, Vol. 61, No. 5, 2004, p. 211-217.

Research output: Contribution to journalArticle

Hubina, E, Mersebach, H, Rasmussen, ÅK, Juul, A, Sneppen, SB, Góth, M & Feldt-Rasmussen, U 2004, 'Effect of growth hormone replacement therapy on pituitary hormone secretion and hormone replacement therapies in GHD adults', Hormone Research, vol. 61, no. 5, pp. 211-217. https://doi.org/10.1159/000076538
Hubina, Erika ; Mersebach, Henriette ; Rasmussen, Åse Krogh ; Juul, Anders ; Sneppen, Simone Bjerregaard ; Góth, M. ; Feldt-Rasmussen, Ulla. / Effect of growth hormone replacement therapy on pituitary hormone secretion and hormone replacement therapies in GHD adults. In: Hormone Research. 2004 ; Vol. 61, No. 5. pp. 211-217.
@article{9db7d4889d2b4a5f9a3067316a085c93,
title = "Effect of growth hormone replacement therapy on pituitary hormone secretion and hormone replacement therapies in GHD adults",
abstract = "Objective: We tested the impact of commencement of GH replacement therapy in GH-deficient (GHD) adults on the circulating levels of other anterior pituitary and peripheral hormones and the need for re-evaluation of other hormone replacement therapies, especially the need for dose changes. Methods: 22 GHD patients were investigated in a double-blind randomized study and 90 GHD patients in an open study at baseline and after 6 and 12 months of GH replacement therapy. Results: In the placebo-controlled trial, the FT 3 levels increased after 6 months in the GH-treated group, and in the open study the FT3 levels tended to increase. Other hormone concentrations did not change in either part of the study. Four patients required an increase in thyroxine dose, while 2 patients needed dose reduction. One originally euthyroid patient required thyroxine replacement. Two patients with originally conserved pituitary-adrenal function developed ACTH insufficiency. The hydrocortisone dose was increased in 1 and decreased in 1 of the 66 patients with secondary hypocortisolism. None of the females required any adjustment of sex hormone replacement therapy. Two of 37 males needed dose increase of testosterone, while 1 needed dose reduction. Conclusion: GH replacement therapy required dose adjustments regarding other hormone replacement therapies in 12.2{\%} (n = 11), while initiation of new hormone replacement was performed in 3.3{\%} (n = 3) of the 90 patients during the 1-year follow-up. Monitoring of pituitary hormone axes is advisable after commencement of GH replacement therapy, since changes of hormone replacement therapy was observed in a small but clinically significant number of patients.",
keywords = "Growth hormone replacement, Pituitary function, Pituitary substitution therapy",
author = "Erika Hubina and Henriette Mersebach and Rasmussen, {{\AA}se Krogh} and Anders Juul and Sneppen, {Simone Bjerregaard} and M. G{\'o}th and Ulla Feldt-Rasmussen",
year = "2004",
doi = "10.1159/000076538",
language = "English",
volume = "61",
pages = "211--217",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Effect of growth hormone replacement therapy on pituitary hormone secretion and hormone replacement therapies in GHD adults

AU - Hubina, Erika

AU - Mersebach, Henriette

AU - Rasmussen, Åse Krogh

AU - Juul, Anders

AU - Sneppen, Simone Bjerregaard

AU - Góth, M.

AU - Feldt-Rasmussen, Ulla

PY - 2004

Y1 - 2004

N2 - Objective: We tested the impact of commencement of GH replacement therapy in GH-deficient (GHD) adults on the circulating levels of other anterior pituitary and peripheral hormones and the need for re-evaluation of other hormone replacement therapies, especially the need for dose changes. Methods: 22 GHD patients were investigated in a double-blind randomized study and 90 GHD patients in an open study at baseline and after 6 and 12 months of GH replacement therapy. Results: In the placebo-controlled trial, the FT 3 levels increased after 6 months in the GH-treated group, and in the open study the FT3 levels tended to increase. Other hormone concentrations did not change in either part of the study. Four patients required an increase in thyroxine dose, while 2 patients needed dose reduction. One originally euthyroid patient required thyroxine replacement. Two patients with originally conserved pituitary-adrenal function developed ACTH insufficiency. The hydrocortisone dose was increased in 1 and decreased in 1 of the 66 patients with secondary hypocortisolism. None of the females required any adjustment of sex hormone replacement therapy. Two of 37 males needed dose increase of testosterone, while 1 needed dose reduction. Conclusion: GH replacement therapy required dose adjustments regarding other hormone replacement therapies in 12.2% (n = 11), while initiation of new hormone replacement was performed in 3.3% (n = 3) of the 90 patients during the 1-year follow-up. Monitoring of pituitary hormone axes is advisable after commencement of GH replacement therapy, since changes of hormone replacement therapy was observed in a small but clinically significant number of patients.

AB - Objective: We tested the impact of commencement of GH replacement therapy in GH-deficient (GHD) adults on the circulating levels of other anterior pituitary and peripheral hormones and the need for re-evaluation of other hormone replacement therapies, especially the need for dose changes. Methods: 22 GHD patients were investigated in a double-blind randomized study and 90 GHD patients in an open study at baseline and after 6 and 12 months of GH replacement therapy. Results: In the placebo-controlled trial, the FT 3 levels increased after 6 months in the GH-treated group, and in the open study the FT3 levels tended to increase. Other hormone concentrations did not change in either part of the study. Four patients required an increase in thyroxine dose, while 2 patients needed dose reduction. One originally euthyroid patient required thyroxine replacement. Two patients with originally conserved pituitary-adrenal function developed ACTH insufficiency. The hydrocortisone dose was increased in 1 and decreased in 1 of the 66 patients with secondary hypocortisolism. None of the females required any adjustment of sex hormone replacement therapy. Two of 37 males needed dose increase of testosterone, while 1 needed dose reduction. Conclusion: GH replacement therapy required dose adjustments regarding other hormone replacement therapies in 12.2% (n = 11), while initiation of new hormone replacement was performed in 3.3% (n = 3) of the 90 patients during the 1-year follow-up. Monitoring of pituitary hormone axes is advisable after commencement of GH replacement therapy, since changes of hormone replacement therapy was observed in a small but clinically significant number of patients.

KW - Growth hormone replacement

KW - Pituitary function

KW - Pituitary substitution therapy

UR - http://www.scopus.com/inward/record.url?scp=1842851841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842851841&partnerID=8YFLogxK

U2 - 10.1159/000076538

DO - 10.1159/000076538

M3 - Article

C2 - 14752209

AN - SCOPUS:1842851841

VL - 61

SP - 211

EP - 217

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 5

ER -